364793-82-8

Basic information

• Product Name: 4-(3-BROMOBENZYL)MORPHOLINE
• Synonyms: 1-[(3-BROMOPHENYL)METHYL]-MORPHOLINE;4-(3-BROMOBENZYL)MORPHOLINE;1-Bromo-3-[(morpholin-4-yl)methyl]benzene;Morpholine,4-[(3-bromophenyl)methyl]-;4-[(3-bromophenyl)methyl]morpholine
• CAS NO: 364793-82-8
• Molecular Formula: C₁₁H₁₄BrNO
• Molecular Weight: 256.14
• Product Categories: Aryl;Organohalides;alkyl bromide
• Mol File: 364793-82-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(3-BROMOBENZYL)MORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-BROMOBENZYL)MORPHOLINE(364793-82-8)
• EPA Substance Registry System: 4-(3-BROMOBENZYL)MORPHOLINE(364793-82-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 364793-82-8(Hazardous Substances Data)

Usage

General Description

4-(3-Bromobenzyl)morpholine, also known as BBrBM, is a chemical compound that belongs to the class of benzylmorpholine derivatives. It is a crystalline solid with a molecular formula C11H14BrNO and a molecular weight of 250.14 g/mol. 4-(3-BROMOBENZYL)MORPHOLINE is commonly used in organic synthesis, medicinal chemistry, and pharmaceutical research as a starting material for the synthesis of various bioactive molecules and pharmaceuticals. It is also known for its potential as an antifungal and antimicrobial agent. Additionally, 4-(3-Bromobenzyl)morpholine has shown promising results in the fields of drug discovery and development due to its diverse pharmacological activities.

Upstream product

• 110-91-8 morpholine 
• 823-78-9 meta-bromobenzyl bromide 
• 3132-99-8 m-bromobenzoic aldehyde 

Downstream Products

• 1010104-38-7 (E)-4-(3-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)benzyl)morpholine 
• 364794-80-9 4-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-morpholine 
• 945537-29-1 C₂₁H₂₂N₂O 
• 446866-83-7 3-(morpholin-4-ylmethyl)benzaldehyde 
• 1432450-84-4 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(3-(morpholinomethyl)phenyl)quinazolin-4-amine 

Relevant articles and documents

Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [18F]-radiolabeling and PET study in rats

In this paper we describe the design and synthesis of bis(Het)Aryl-1,2,3-triazole quinuclidine α7R ligands using an efficient three-step sequence including a Suzuki-Miyaura cross coupling reaction with commercially available and home-made boron derivatives. The exploration of SAR required the preparation of uncommon boron derivatives. Forty final drugs were tested for their ability to bind the target and nine of them exhibited Ki values below nanomolar concentrations. The best scores were always obtained when the 5-phenyl-2-thiophenyl core was attached to the triazole. The selectivity of these compounds towards the nicotinic α4β2 and serotoninergic 5HT3 receptors was assessed and their brain penetration was quantified by the preparation and in vivo evaluation of two [18F] radiolabelled derivatives. It can be expected from our results that some of these compounds will be suitable for further developments and will have effects on cognitive disorders.

CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS

The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors. Formula(I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.